XOMA Royalty (NASDAQ:XOMA) Stock Rating Upgraded by Zacks Research

XOMA Royalty (NASDAQ:XOMA) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other brokerages also recently weighed in on XOMA. Wall Street Zen downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. UBS Group set a $76.00 target price on XOMA Royalty in a report on Tuesday, December 9th. Benchmark restated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a research report on Monday, December 29th. Finally, Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a research note on Friday, December 12th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.60.

XOMA Royalty Stock Up 0.2%

XOMA Royalty stock traded up $0.06 during midday trading on Monday, reaching $22.95. The stock had a trading volume of 15,993 shares, compared to its average volume of 662,664. The firm’s fifty day simple moving average is $26.87 and its 200-day simple moving average is $31.20. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. The stock has a market capitalization of $284.07 million, a P/E ratio of 31.28 and a beta of 0.86. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The company had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. As a group, analysts expect that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Owen Hughes bought 100,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were purchased at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the acquisition, the chief executive officer owned 102,000 shares of the company’s stock, valued at $2,555,100. This represents a 5,000.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in XOMA. State of Alaska Department of Revenue acquired a new position in XOMA Royalty in the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. increased its position in XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 756 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares during the period. JPMorgan Chase & Co. boosted its holdings in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in XOMA Royalty in the second quarter valued at approximately $116,000. 95.92% of the stock is owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.